933 reports of this reaction
5.9% of all FAM TRASTUZUMAB DERUXTECAN NXKI reports
#2 most reported adverse reaction
INTERSTITIAL LUNG DISEASE is the #2 most commonly reported adverse reaction for FAM TRASTUZUMAB DERUXTECAN NXKI, manufactured by Daiichi Sankyo Inc.. There are 933 FDA adverse event reports linking FAM TRASTUZUMAB DERUXTECAN NXKI to INTERSTITIAL LUNG DISEASE. This represents approximately 5.9% of all 15,771 adverse event reports for this drug.
Patients taking FAM TRASTUZUMAB DERUXTECAN NXKI who experience interstitial lung disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTERSTITIAL LUNG DISEASE is moderately reported among FAM TRASTUZUMAB DERUXTECAN NXKI users, representing a notable but not dominant share of adverse events.
In addition to interstitial lung disease, the following adverse reactions have been reported for FAM TRASTUZUMAB DERUXTECAN NXKI:
The following drugs have also been linked to interstitial lung disease in FDA adverse event reports:
INTERSTITIAL LUNG DISEASE has been reported as an adverse event in 933 FDA reports for FAM TRASTUZUMAB DERUXTECAN NXKI. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTERSTITIAL LUNG DISEASE accounts for approximately 5.9% of all adverse event reports for FAM TRASTUZUMAB DERUXTECAN NXKI, making it one of the most commonly reported side effect.
If you experience interstitial lung disease while taking FAM TRASTUZUMAB DERUXTECAN NXKI, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.